Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.40 |
| ▸ | CA1 | P00915 | 11/20 | 0.39 |
| ▸ | MMP1 | P03956 | 5/20 | 0.39 |
| ▸ | MMP2 | P08253 | 5/20 | 0.39 |
| ▸ | MMP9 | P14780 | 5/20 | 0.39 |
| ▸ | MMP8 | P22894 | 5/20 | 0.39 |
| ▸ | MMP13 | P45452 | 5/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960778 | 0.98 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5960798 | 0.98 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5960736 | 0.98 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5960751 | 0.98 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5960765 | 0.98 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5960743 | 0.98 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5960742 | 0.93 | CA2 (0.32) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL4082883 | 0.84 | — | — | |
| SCHEMBL5960805 | 0.82 | CA2 (0.36) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5960775 | 0.80 | CA2 (0.39) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11469447-B2 | Silicon-based energy storage devices with electrolyte containing sulfonate or carboxylate salt based compounds | ENEVATE CORPORATION (US) | 2022-10-11 | — | — | US | claimed |
| CN-114423771-A | Method for producing nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts themselves and use thereof | 生物合成股份公司 | 2022-04-29 | — | — | CN | claimed |
| US-20210194056-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING SULFONATE OR CARBOXYLATE SALT BASED COMPOUNDS | ENEVATE CORPORATION | 2021-06-24 | — | — | US | claimed |
| CN-105845980-B | Electrolyte and lithium ion battery containing same | 宁德时代新能源科技股份有限公司 | 2020-05-05 | — | — | CN | claimed |
| EP-3303451-B1 | SUPER ACIDS AND BASES AS DEHYDROCONDENSATION CATALYSTS | MOMENTIVE PERFORMANCE MAT INC (US) | 2019-08-21 | — | — | EP | claimed |
| WO-2015175521-A1 | METHOD AND SYSTEM TO IMPROVE DRYING OF FLEXIBLE NANO-STRUCTURES | TOKYO ELECTRON LIMITED (JP) | 2015-11-19 | — | — | WO | claimed |
| US-20150325458-A1 | METHOD AND SYSTEM TO IMPROVE DRYING OF FLEXIBLE NANO-STRUCTURES | TOKYO ELECTRON LIMITED (JP) | 2015-11-12 | — | — | US | claimed |
| EP-1853616-B1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA-ANOMER ENRICHED 2'-DEOXY,2',2'-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | FRESENIUS KABI ONCOLOGY LTD (IN) | 2010-02-24 | — | — | EP | claimed |
| EP-1853616-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA-ANOMER ENRICHED 21-DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | Dabur Pharma Limited (IN) | 2007-11-14 | — | — | EP | claimed |
| US-20070208170-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA- ANOMER ENRICHED 21-DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | DABUR PHARMA LIMITED | 2007-09-06 | — | — | US | claimed |
| US-7235647-B2 | Intermediate and process for preparing of β- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides | DABUR PHARMA LIMITED (IN) | 2007-06-26 | — | — | US | claimed |
| US-20060217547-A1 | Intermediate and process for preparing of beta- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2006-09-28 | — | — | US | claimed |
| WO-2006092808-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA- ANOMER ENRICHED 21DEOXY, 21 ,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | DABUR PHARMA LIMITED (IN) | 2006-09-08 | — | — | WO | claimed |
| EP-0165393-B1 | HERBICIDAL AGENT | AGROLINZ AGRARCHEMIKALIEN GESELLSCHAFT M.B.H. (AT) | 1988-11-02 | — | — | EP | claimed |
| EP-0143323-B1 | PROCESS FOR AN ANTHRACYCLINE DERIVATIVE, AND AN ANTHRACYCLINONE DERIVATIVE USEFUL FOR THE PROCESS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1988-10-26 | — | — | EP | claimed |
| EP-0195963-A1 | Process for the preparation of carbapenem intermediates | BAYER AG (DE) | 1986-10-01 | — | — | EP | claimed |
| US-4564674-A | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-01-14 | — | — | US | claimed |
| EP-0165393-A1 | Herbicidal agent | AGROLINZ AGRARCHEMIKALIEN GESELLSCHAFT M.B.H. (AT) | 1985-12-27 | — | — | EP | claimed |
| EP-0143323-A2 | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-06-05 | — | — | EP | claimed |
| US-20250243234-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | BIOSYNTH AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-12358940-B2 | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | BIOSYNTH AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-12344629-B2 | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | BIOSYNTH AG (CH) | 2025-07-01 | — | — | US | disclosed |
| US-20250110101-A1 | PER AND POLYFLUOROALKYL SUBSTANCE MEASUREMENT | DEXSIL CORPORATION (US) | 2025-04-03 | — | — | US | disclosed |
| CN-119684381-A | Crystalline forms of nicotinamide riboside furanoside salts and nutritional supplements and pharmaceutical compositions containing same | 生物合成股份公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250092079-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | BIOSYNTH AG | 2025-03-20 | — | — | US | disclosed |
| CN-119462782-A | Method for producing nicotinamide riboside salts, nicotinamide riboside salts per se and use thereof | 生物合成股份公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119278504-A | Substrate processing method and substrate manufacturing method | 中央硝子株式会社 | 2025-01-07 | — | — | CN | disclosed |
| CN-119278503-A | Substrate processing method and substrate manufacturing method | 中央硝子株式会社 | 2025-01-07 | — | — | CN | disclosed |
| EP-4471043-A2 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | Biosynth AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| EP-4471042-A2 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | Biosynth AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20240059727-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS BY SALT METATHESIS, THE CRYSTALLINE FORM OF ITS TOSYLATE SALT AND THE CO-CRYSTALLIZED FORM OF ITS CHLORIDE:IODIDE SALT | BIOSYNTH AG (CH) | 2024-02-22 | — | — | US | disclosed |
| US-20240059860-A1 | METHODS AND SYSTEMS FOR DESTRUCTION OF SYNTHETIC PER- AND POLYFLUORO COMPOUNDS | CHZ TECHNOLOGIES, LLC | 2024-02-22 | — | — | US | disclosed |
| EP-4281465-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS BY SALT METATHESIS, THE CRYSTALLINE FORM OF ITS TOSYLATE SALT AND THE CO-CRYSTALLIZED FORM OF ITS CHLORIDE:IODIDE SALT | Biosynth AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11749839-B2 | Silicon-based energy storage devices with electrolyte containing sulfonate or carboxylate salt based compounds | ENEVATE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230178803-A1 | Silicon-Based Energy Storage Devices With Electrolyte Containing Sulfonate or Carboxylate Salt Based Compounds | ENEVATE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-11584771-B2 | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | BIOSYNTH AG (CH) | 2023-02-21 | — | — | US | disclosed |
| CN-115699259-A | Surface treatment method for semiconductor substrate and surface treatment agent composition | 中央硝子株式会社 | 2023-02-03 | — | — | CN | disclosed |
| CN-115668459-A | Surface treatment method for semiconductor substrate and surface treatment agent composition | 中央硝子株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-11469447-B2 | Silicon-based energy storage devices with electrolyte containing sulfonate or carboxylate salt based compounds | ENEVATE CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220251133-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | BIOSYNTH AG (CH) | 2022-08-11 | — | — | US | disclosed |
| WO-2022157173-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS BY SALT METATHESIS, THE CRYSTALLINE FORM OF ITS TOSYLATE SALT AND THE CO-CRYSTALLIZED FORM OF ITS CHLORIDE:IODIDE SALT | BIOSYNTH AG (CH) | 2022-07-28 | — | — | WO | disclosed |
| EP-3999518-A2 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | Biosynth AG (CH) | 2022-05-25 | — | — | EP | disclosed |
| US-20220135610-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | BIOSYNTH AG (CH) | 2022-05-05 | — | — | US | disclosed |
| CN-114423771-A | Method for producing nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts themselves and use thereof | 生物合成股份公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210194056-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING SULFONATE OR CARBOXYLATE SALT BASED COMPOUNDS | ENEVATE CORPORATION | 2021-06-24 | — | — | US | disclosed |
| WO-2021013795-A2 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | BIOSYNTH AG (CH) | 2021-01-28 | — | — | WO | disclosed |
| US-10688217-B2 | Amine-functionalized polymeric compositions for medical devices | KCI LICENSING, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| CN-105845980-B | Electrolyte and lithium ion battery containing same | 宁德时代新能源科技股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| EP-3611205-A1 | SULFHYDRYL-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES | KCI Licensing, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10450251-B2 | Process for the preparation of 3-substituted cannabinoid compounds | E-THERAPEUTICS PLC (GB) | 2019-10-22 | — | — | US | disclosed |
| EP-3303451-B1 | SUPER ACIDS AND BASES AS DEHYDROCONDENSATION CATALYSTS | MOMENTIVE PERFORMANCE MAT INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20180354876-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | E-THERAPEUTICS PLC (GB) | 2018-12-13 | — | — | US | disclosed |
| EP-3383832-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | e-Therapeutics plc (GB) | 2018-10-10 | — | — | EP | disclosed |
| US-10053532-B2 | Sulfhydryl-functionalized polymeric compositions for medical devices | KCI LICENSING, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180085489-A1 | AMINE-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2018-03-29 | — | — | US | disclosed |
| US-9901912-B2 | Super acids and bases as dehydrocondensation catalysts | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9861723-B2 | Amine-functionalized polymeric compositions for medical devices | KCI LICENSING, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9847302-B2 | Wafer surface conditioning for stability in fab environment | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2017-12-19 | — | — | US | disclosed |
| US-20170246341-A1 | AMINE-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-08-31 | — | — | US | disclosed |
| US-20170190828-A1 | SULFHYDRYL-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-07-06 | — | — | US | disclosed |
| WO-2017102055-A1 | METHOD FOR PRODUCING SALTS WITH MONOFLUOROTRICYANOBORATE ANIONS | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017093749-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | E-THERAPEUTICS PLC (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-9657132-B2 | Amine-functionalized polymeric compositions for medical devices | KCI LICENSING, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9616151-B2 | Sulfhydryl-functionalized polymeric compositions for medical devices | KCI LICENSING, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160354769-A1 | SUPER ACIDS AND BASES AS DEHYDROCONDENSATION CATALYSTS | MOMENTIVE PERFORMANCE MATERIALS INC. | 2016-12-08 | — | — | US | disclosed |
| WO-2015175521-A1 | METHOD AND SYSTEM TO IMPROVE DRYING OF FLEXIBLE NANO-STRUCTURES | TOKYO ELECTRON LIMITED (JP) | 2015-11-19 | — | — | WO | disclosed |
| US-20150325458-A1 | METHOD AND SYSTEM TO IMPROVE DRYING OF FLEXIBLE NANO-STRUCTURES | TOKYO ELECTRON LIMITED (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150265743-A1 | Sulfhydryl-Functionalized Polymeric Compositions For Medical Devices | KCI USA, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150246995-A1 | Amine-Functionalized Polymeric Compositions For Medical Devices | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-09-03 | — | — | US | disclosed |
| EP-2912088-A1 | SULFHYDRYL-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES | KCI Licensing, Inc. (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2912087-A1 | AMINE-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES | KCI Licensing, Inc. (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20150054142-A1 | Wafer Surface Conditioning for Stability in Fab Environment | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2015-02-26 | — | — | US | disclosed |
| WO-2014066674-A1 | AMINE-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES | KCI LICENSING, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014066684-A1 | SULFHYDRYL-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES | KCI LICENSING, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| EP-1853616-B1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA-ANOMER ENRICHED 2'-DEOXY,2',2'-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | FRESENIUS KABI ONCOLOGY LTD (IN) | 2010-02-24 | — | — | EP | disclosed |
| EP-1706414-B1 | PROCESS FOR FLUOROCYTIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7365188-B2 | Process for producing N4-Acyl-5′-deoxy-5-fluorocytidine | ROCHE COLORADO CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1853616-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA-ANOMER ENRICHED 21-DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | Dabur Pharma Limited (IN) | 2007-11-14 | — | — | EP | disclosed |
| US-20070208170-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA- ANOMER ENRICHED 21-DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | DABUR PHARMA LIMITED | 2007-09-06 | — | — | US | disclosed |
| US-7235647-B2 | Intermediate and process for preparing of β- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides | DABUR PHARMA LIMITED (IN) | 2007-06-26 | — | — | US | disclosed |
| EP-1706414-A2 | PROCESS FOR FLUOROCYTIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| US-20060217547-A1 | Intermediate and process for preparing of beta- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2006-09-28 | — | — | US | disclosed |
| WO-2006092808-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA- ANOMER ENRICHED 21DEOXY, 21 ,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | DABUR PHARMA LIMITED (IN) | 2006-09-08 | — | — | WO | disclosed |
| EP-1688423-A1 | Silylation of hydroxyl group-containing compounds | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1334975-B1 | Silylation of hydroxyl group-containing compounds | SHINETSU CHEMICAL CO (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005063786-A2 | PROCESS FOR FLUOROCYTIDINE DERIVATIVES | F.HOFFMAN-LA ROCHE AG (CH) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137392-A1 | Process for producing N4-Acyl-5'-deoxy-5-fluorocytidine | ROCHE COLORADO CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| US-6875880-B2 | Silylation of hydroxyl groups | SHIN-ETSU CHEMICAL, CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-6777549-B2 | PRODUCING CEFTRIAXONE OR CEFOTAXIME BY AMIDATION, CYCLIZATION, DESILYLATION AND OPTIONALLY SALT FORMATION | SANDOZ GMBH (AT) | 2004-08-17 | — | — | US | disclosed |
| EP-1334975-A1 | Silylation of hydroxyl group-containing compounds | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030139619-A1 | Silylation of hydroxyl groups | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-0985674-B1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR ALPHA-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING ALPHA-OLEFIN POLYMERS | MITSUBISHI CHEM CORP (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6552186-B2 | Ceftrixone, cefotaxime or derivatives | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2003-04-22 | — | — | US | disclosed |
| US-20020156272-A1 | Beta-lactam production | GERLACH BENJAMIN (AT) | 2002-10-24 | — | — | US | disclosed |
| US-20020128469-A1 | Beta-lactam production | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2002-09-12 | — | — | US | disclosed |
| US-6433174-B1 | Process for producing novel naphthyridine derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6358665-B1 | ONIUM SALT PRECURSOR FOR GENERATING FLUOROALKYLSULFONATE | CLARIANT INTERNATIONAL LTD. (CH) | 2002-03-19 | — | — | US | disclosed |
| EP-1169324-A1 | BETA-LACTAM PRODUCTION | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2002-01-09 | — | — | EP | disclosed |
| EP-1142892-A1 | PROCESSES FOR THE PREPARATION OF NOVEL NAPHTHYRIDINE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6255515-B1 | COORDINATION POLYMERIZATION CATALYSTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-07-03 | — | — | US | disclosed |
| WO-2000063214-A1 | BETA-LACTAM PRODUCTION | BIOCHEMIE GESELLSCHAFT M B H (AT) | 2000-10-26 | — | — | WO | disclosed |
| EP-1033624-A1 | RADIATION-SENSITIVE COMPOSITION OF CHEMICAL AMPLIFICATION TYPE | Clariant International Ltd. (CH) | 2000-09-06 | — | — | EP | disclosed |
| EP-0985674-A1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5705702-A | REACTING AN ARYL GRIGNARD REAGENT WITH THIONYL CHLORIDE, THEN WITH TRIORGANOSILYL SULFONATE OR TRIORGANOSILYLHALIDE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| US-5476892-A | Mixing with a silylated acid; good color and activity properties; producing polyurethane foams | BAYER AKTIENGESELLSCHAFT (DE) | 1995-12-19 | — | — | US | disclosed |
| US-5286901-A | Prescursors for and synthesis of mono- and difunctionalized acetylenes and difunctional 1,3-diynes | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1994-02-15 | — | — | US | disclosed |
| EP-0247431-B1 | SUBSTITUTED 6-HYDROXYMETHYLCARBAPENEM ANTIBIOTICS, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4863916-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-05 | — | — | US | disclosed |
| US-4841042-A | Process for the preparation of carbapenem intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-20 | — | — | US | disclosed |
| EP-0165393-B1 | HERBICIDAL AGENT | AGROLINZ AGRARCHEMIKALIEN GESELLSCHAFT M.B.H. (AT) | 1988-11-02 | — | — | EP | disclosed |
| EP-0143323-B1 | PROCESS FOR AN ANTHRACYCLINE DERIVATIVE, AND AN ANTHRACYCLINONE DERIVATIVE USEFUL FOR THE PROCESS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1988-10-26 | — | — | EP | disclosed |
| EP-0247431-A1 | Substituted 6-hydroxymethylcarbapenem antibiotics, process for their preparation and their use | BAYER AG (DE) | 1987-12-02 | — | — | EP | disclosed |
| US-4565883-A | Cyanoacrylate adhesive composition | TEROSON GMBH (DE) | 1986-01-21 | — | — | US | disclosed |
| US-4564674-A | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0165393-A1 | Herbicidal agent | AGROLINZ AGRARCHEMIKALIEN GESELLSCHAFT M.B.H. (AT) | 1985-12-27 | — | — | EP | disclosed |
| EP-0143323-A2 | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-06-05 | — | — | EP | disclosed |
| EP-0143323-A2 | Process for an anthracycline derivative, and an anthracyclinone derivative useful for the process | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059727-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS BY SALT METATHESIS, THE CRYSTALLINE FORM OF ITS TOSYLATE SALT AND THE CO-CRYSTALLIZED FORM OF ITS CHLORIDE:IODIDE SALT | NNMT, NAMPT, COASY | CA2 649/4885CA1 744/4885MMP1 826/4885 |
| US-10688217-B2 | Amine-functionalized polymeric compositions for medical devices | ADM2, MSN, FGB | CA2 4697/4885CA1 4417/4885MMP1 630/4885 |
| US-20070208170-A1 | INTERMEDIATE AND PROCESS FOR PREPARING OF BETA- ANOMER ENRICHED 21-DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES | GART, ST6GAL1, B4GALT1 | CA2 2694/4885CA1 1016/4885MMP1 4051/4885 |
| US-20250092079-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | NAMPT, NNT, NADK | CA2 1480/4885CA1 2557/4885MMP1 3438/4885 |
| US-20250243234-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | NAMPT, NNT, NADK | CA2 1337/4885CA1 2279/4885MMP1 3293/4885 |
| US-20220135610-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | NAMPT, NNT, NADK | CA2 1337/4885CA1 2279/4885MMP1 3293/4885 |
| US-11584771-B2 | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | NAMPT, NNT, NADK | CA2 1480/4885CA1 2557/4885MMP1 3438/4885 |
| US-20180354876-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | CNR1, CNR2, OPRK1 | CA2 3177/4885CA1 1337/4885MMP1 4542/4885 |
| US-12358940-B2 | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | NAMPT, NNT, NADK | CA2 1480/4885CA1 2557/4885MMP1 3438/4885 |
| US-20050137392-A1 | Process for producing N4-Acyl-5'-deoxy-5-fluorocytidine | RNGTT, DUT, DCK | CA2 4645/4885CA1 4720/4885MMP1 4556/4885 |
| US-20060217547-A1 | Intermediate and process for preparing of beta- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides | GART, ST6GAL1, B4GALT1 | CA2 2694/4885CA1 1016/4885MMP1 4051/4885 |
| US-10450251-B2 | Process for the preparation of 3-substituted cannabinoid compounds | CNR1, CNR2, CBR1 | CA2 3089/4885CA1 1341/4885MMP1 4451/4885 |
| US-20020156272-A1 | Beta-lactam production | MRPL21, COASY, Q6ZSR9 | CA2 992/4885CA1 2413/4885MMP1 2034/4885 |
| US-20020128469-A1 | Beta-lactam production | MRPL21, COASY, Q6ZSR9 | CA2 992/4885CA1 2413/4885MMP1 2034/4885 |
| US-20160354769-A1 | SUPER ACIDS AND BASES AS DEHYDROCONDENSATION CATALYSTS | STS, DHPS, FDFT1 | CA2 195/4885CA1 6/4885MMP1 2419/4885 |
| US-20220251133-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | NAMPT, NNT, NADK | CA2 1480/4885CA1 2557/4885MMP1 3438/4885 |
| US-12344629-B2 | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | NAMPT, NNT, NADK | CA2 1337/4885CA1 2279/4885MMP1 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.